Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

: Saxagliptin is a selective and potent dipeptidyl peptidase (DPP)-4 did not increase or decrease the rate of ischemic events, although the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. Saxagliptin is applicable for various pathological conditions, and is considered to be clinically significant as a new therapeutic option for Japanese patients with T2DM. OHA, 6.25 μ g/mL in α -glycosidase inhibitors CTG patients, by 3.67 μ g/mL from a baseline of 5.29 μ g/mL in biguanides CTG patients, by 3.33 μ g/mL from a baseline of 3.96 μ g/mL in TZDs CTG patients, and by 3.88 μ g/mL from a baseline of 6.45 μ g/mL in glinides CTG patients. 40 These data suggest that saxagliptin clearly improves fasting and postprandial hyperglycemia in patients with T2DM. Long-term combination therapy with saxagliptin and other oral hypoglycemic agents provided sustained glycemic and was well for up to 52 weeks. 42,45